Semaglutide is a GLP-1 receptor agonist with extensive published human trial literature as an approved drug product. Catalog research peptide labeled semaglutide is a separate RUO material — not interchangeable with pharmaceutical formulations without verified identity and context.
Tirzepatide combines GIP and GLP-1 receptor agonism in a single acylated peptide — a distinct research object from GLP-1–selective molecules like semaglutide, with large published SURPASS and SURMOUNT trial programs.
Retatrutide is a development-stage triple agonist adding glucagon receptor activity to dual incretin pharmacology. Human data are earlier and narrower than for semaglutide or tirzepatide, with active phase 2 literature.
Cagrilintide is a long-acting amylin analog studied in combination with GLP-1 agonists in metabolic research programs. It extends the incretin research arc with amylin-pathway biology distinct from GLP-1 alone.
AOD-9604 is marketed as a fragment of human growth hormone associated with lipolytic research interest. Published literature is sparse relative to incretin peptides, and catalog identity verification is essential.
Exenatide is the first-in-class GLP-1 receptor agonist based on exendin-4 from Gila monster venom, with long-standing human trial literature. It anchors incretin research history before later acylated analogs like liraglutide and semaglutide.
Liraglutide is an earlier-generation acylated GLP-1 receptor agonist with extensive published trial literature as an approved drug. Catalog research peptide labeled liraglutide is separate RUO material requiring full acylation verification.
Mazdutide is a dual GLP-1 and glucagon receptor agonist in active clinical development, studied in obesity and type 2 diabetes research programs. Evidence maturity is earlier than for semaglutide or tirzepatide.
Survodutide is a dual GLP-1/glucagon receptor agonist studied in metabolic and MASH (NAFLD/NASH) research trials. Human data are phase 2–stage, narrower than established incretin drugs.
Community content — not medical advice. Research use only; nothing here is instruction for human use.
We use strictly necessary cookies to run the site (your sign-in session and this choice). With your consent we also use analytics cookies to improve the site. See our Cookie Policy and Privacy Policy.